Federal Circuit: Generic Cos. Can Be Sued Where They Compete
This article was originally published in Scrip
Executive Summary
A three-judge panel from the US Court of Appeals for the Federal Circuit on March 18 said generic drug makers can be sued for patent infringement in any US jurisdiction where those firms plan to compete – upholding two separate Delaware judges' decisions to deny motions by Mylan NV to dismiss separate lawsuits brought against it by AstraZeneca PLC and Acorda Therapeutics Inc.